Chair
Member
Audit Committee Position

Paul Van Damme, B COMM, CPA, MBA

Paul Van Damme has held senior positions with a number of Canadian and US public companies. His experience focused on the biotech industry in Toronto when he joined GlycoDesign, a private biotech company. While at Allelix Pharmaceuticals Inc., he participated in the sale of that company to NPS Pharmaceuticals, Inc. Paul is Managing Director, WCM Capital, a Director of OncoQuest Inc. and Chief Financial Officer for Structural Genomics Consortium, a UK-based charity. He holds a B.Comm. from the University of Toronto and a MBA from the Rotman School of Management. A Chartered Professional Accountant who worked for PricewaterhouseCoopers in its Toronto and London, UK offices, he has also been appointed Chair of the XORTX Audit Committee.

Chair

Ian Klassen

Ian Klassen brings almost 30 years of business management, public relations and government affairs experience to XORTX. He has extensive experience in the administration of public companies, finance, government policy, media relationship strategies, business/government project management and legislative decision-making. He previously served as Chief of Staff to the Canadian Speaker of the House of Commons. He is currently the President & CEO of two gold exploration companies listed on the TSX Venture Exchange and was a founding director of Canabo Medical Corp. a public company which for a period of time operated Canada’s largest group of physician-led referral-only clinics for medical cannabis. Canabo completed a business combination with Aleafia Health Inc. in March 2018. Ian has extensive experience chairing governance, audit, risk assessment and compensation committees. He holds a B.A. (Honours) from the University of Western Ontario and is a recipient of the Commemorative Medal for the 125th Anniversary of the Confederation of Canada in recognition of his significant contribution to his community and country.

Member

Bruce Rowlands

Bruce Rowlands has held the position of Chairman since May 2018 and a director of XORTX Pharma Corp., the Company’s predecessor since 2014. Bruce is the former Chairman and CEO of Eurocontrol Technics Group Inc., a TSX Venture Exchange listed company. Prior to forming Eurocontrol, Bruce worked in the biotechnology and investment banking industries as Senior Vice President with Lorus Therapeutics, Inc. a leading Canadian biotechnology company and Vice President and Director of Dominick and Dominick Securities Canada, a Canadian investment banking firm.

Member

Audit Committee Charter

Download
Compensation Committee Position

Ian Klassen

Ian Klassen brings almost 30 years of business management, public relations and government affairs experience to XORTX. He has extensive experience in the administration of public companies, finance, government policy, media relationship strategies, business/government project management and legislative decision-making. He previously served as Chief of Staff to the Canadian Speaker of the House of Commons. He is currently the President & CEO of two gold exploration companies listed on the TSX Venture Exchange and was a founding director of Canabo Medical Corp. a public company which for a period of time operated Canada’s largest group of physician-led referral-only clinics for medical cannabis. Canabo completed a business combination with Aleafia Health Inc. in March 2018. Ian has extensive experience chairing governance, audit, risk assessment and compensation committees. He holds a B.A. (Honours) from the University of Western Ontario and is a recipient of the Commemorative Medal for the 125th Anniversary of the Confederation of Canada in recognition of his significant contribution to his community and country.

Chair

William Farley

Bill Farley has over 35 years experience in the Business Development, Sales and leading efforts in drug discovery, development and partnering. Prior to joining the board of directors of XORTX, Mr. Farley held a senior leadership position at Sorrento Therapeutics. Bill, began his career at Johnson and Johnson and has also held senior management positions at Pfizer and HitGen Ltd. and Vice President, WuXi Apptec, Inc. creating, building and leading global business development teams, and Vice President, Business Development at ChemDiv where he led numerous efforts to create new therapeutic companies in CNS, Oncology and Anti infectives. Mr. Farley serves on the board of directors of SOMA and as a consultant to various executive management teams as well as advising several board of directors on commercialization of assets. Mr. Farley has spoken at numerous conferences and is published in variety of journals. He received his Bachelor of Science degree in Chemistry from State University of New York, Oswego and graduate courses at Rutgers and University of California, Irvine.

Member

Paul Van Damme, B COMM, CPA, MBA

Paul Van Damme has held senior positions with a number of Canadian and US public companies. His experience focused on the biotech industry in Toronto when he joined GlycoDesign, a private biotech company. While at Allelix Pharmaceuticals Inc., he participated in the sale of that company to NPS Pharmaceuticals, Inc. Paul is Managing Director, WCM Capital, a Director of OncoQuest Inc. and Chief Financial Officer for Structural Genomics Consortium, a UK-based charity. He holds a B.Comm. from the University of Toronto and a MBA from the Rotman School of Management. A Chartered Professional Accountant who worked for PricewaterhouseCoopers in its Toronto and London, UK offices, he has also been appointed Chair of the XORTX Audit Committee.

Member

Compensation Committee Charter

Download
Corporate Governance and Nominating Committee Position

Jacqueline Le Saux

Jacqueline Le Saux is a seasoned Canadian health care legal executive who has held senior positions at large and small public and private life science companies. Jacqueline’s legal experience is focused on securities, pharmaceutical regulatory and intellectual property law. As a Vice President, Legal in both public and private companies Ms. Le Saux has led multiple financings, mergers and acquisitions and product licensing transactions, mitigating risk and executing strategies in the Canadian healthcare industry. Her broad industry experience spans big pharma to early and late-stage research and development, as well as consumer products and pharmaceutical manufacturing. Prior to entering the health care industry, she was a partner at a top tier Canadian law firm, specializing in securities and corporate law.

Chair

Bruce Rowlands

Bruce Rowlands has held the position of Chairman since May 2018 and a director of XORTX Pharma Corp., the Company’s predecessor since 2014. Bruce is the former Chairman and CEO of Eurocontrol Technics Group Inc., a TSX Venture Exchange listed company. Prior to forming Eurocontrol, Bruce worked in the biotechnology and investment banking industries as Senior Vice President with Lorus Therapeutics, Inc. a leading Canadian biotechnology company and Vice President and Director of Dominick and Dominick Securities Canada, a Canadian investment banking firm.

Member

Paul Van Damme, B COMM, CPA, MBA

Paul Van Damme has held senior positions with a number of Canadian and US public companies. His experience focused on the biotech industry in Toronto when he joined GlycoDesign, a private biotech company. While at Allelix Pharmaceuticals Inc., he participated in the sale of that company to NPS Pharmaceuticals, Inc. Paul is Managing Director, WCM Capital, a Director of OncoQuest Inc. and Chief Financial Officer for Structural Genomics Consortium, a UK-based charity. He holds a B.Comm. from the University of Toronto and a MBA from the Rotman School of Management. A Chartered Professional Accountant who worked for PricewaterhouseCoopers in its Toronto and London, UK offices, he has also been appointed Chair of the XORTX Audit Committee.

Member

Corporate Governance and Nominating Committee Charter

Download

Paul Van Damme, B COMM, CPA, MBA

Paul Van Damme has held senior positions with a number of Canadian and US public companies. His experience focused on the biotech industry in Toronto when he joined GlycoDesign, a private biotech company. While at Allelix Pharmaceuticals Inc., he participated in the sale of that company to NPS Pharmaceuticals, Inc. Paul is Managing Director, WCM Capital, a Director of OncoQuest Inc. and Chief Financial Officer for Structural Genomics Consortium, a UK-based charity. He holds a B.Comm. from the University of Toronto and a MBA from the Rotman School of Management. A Chartered Professional Accountant who worked for PricewaterhouseCoopers in its Toronto and London, UK offices, he has also been appointed Chair of the XORTX Audit Committee.

Ian Klassen

Ian Klassen brings almost 30 years of business management, public relations and government affairs experience to XORTX. He has extensive experience in the administration of public companies, finance, government policy, media relationship strategies, business/government project management and legislative decision-making. He previously served as Chief of Staff to the Canadian Speaker of the House of Commons. He is currently the President & CEO of two gold exploration companies listed on the TSX Venture Exchange and was a founding director of Canabo Medical Corp. a public company which for a period of time operated Canada’s largest group of physician-led referral-only clinics for medical cannabis. Canabo completed a business combination with Aleafia Health Inc. in March 2018. Ian has extensive experience chairing governance, audit, risk assessment and compensation committees. He holds a B.A. (Honours) from the University of Western Ontario and is a recipient of the Commemorative Medal for the 125th Anniversary of the Confederation of Canada in recognition of his significant contribution to his community and country.

Bruce Rowlands

Bruce Rowlands has held the position of Chairman since May 2018 and a director of XORTX Pharma Corp., the Company’s predecessor since 2014. Bruce is the former Chairman and CEO of Eurocontrol Technics Group Inc., a TSX Venture Exchange listed company. Prior to forming Eurocontrol, Bruce worked in the biotechnology and investment banking industries as Senior Vice President with Lorus Therapeutics, Inc. a leading Canadian biotechnology company and Vice President and Director of Dominick and Dominick Securities Canada, a Canadian investment banking firm.

Ian Klassen

Ian Klassen brings almost 30 years of business management, public relations and government affairs experience to XORTX. He has extensive experience in the administration of public companies, finance, government policy, media relationship strategies, business/government project management and legislative decision-making. He previously served as Chief of Staff to the Canadian Speaker of the House of Commons. He is currently the President & CEO of two gold exploration companies listed on the TSX Venture Exchange and was a founding director of Canabo Medical Corp. a public company which for a period of time operated Canada’s largest group of physician-led referral-only clinics for medical cannabis. Canabo completed a business combination with Aleafia Health Inc. in March 2018. Ian has extensive experience chairing governance, audit, risk assessment and compensation committees. He holds a B.A. (Honours) from the University of Western Ontario and is a recipient of the Commemorative Medal for the 125th Anniversary of the Confederation of Canada in recognition of his significant contribution to his community and country.

William Farley

Bill Farley has over 35 years experience in the Business Development, Sales and leading efforts in drug discovery, development and partnering. Prior to joining the board of directors of XORTX, Mr. Farley held a senior leadership position at Sorrento Therapeutics. Bill, began his career at Johnson and Johnson and has also held senior management positions at Pfizer and HitGen Ltd. and Vice President, WuXi Apptec, Inc. creating, building and leading global business development teams, and Vice President, Business Development at ChemDiv where he led numerous efforts to create new therapeutic companies in CNS, Oncology and Anti infectives. Mr. Farley serves on the board of directors of SOMA and as a consultant to various executive management teams as well as advising several board of directors on commercialization of assets. Mr. Farley has spoken at numerous conferences and is published in variety of journals. He received his Bachelor of Science degree in Chemistry from State University of New York, Oswego and graduate courses at Rutgers and University of California, Irvine.

Paul Van Damme, B COMM, CPA, MBA

Paul Van Damme has held senior positions with a number of Canadian and US public companies. His experience focused on the biotech industry in Toronto when he joined GlycoDesign, a private biotech company. While at Allelix Pharmaceuticals Inc., he participated in the sale of that company to NPS Pharmaceuticals, Inc. Paul is Managing Director, WCM Capital, a Director of OncoQuest Inc. and Chief Financial Officer for Structural Genomics Consortium, a UK-based charity. He holds a B.Comm. from the University of Toronto and a MBA from the Rotman School of Management. A Chartered Professional Accountant who worked for PricewaterhouseCoopers in its Toronto and London, UK offices, he has also been appointed Chair of the XORTX Audit Committee.

Jacqueline Le Saux

Jacqueline Le Saux is a seasoned Canadian health care legal executive who has held senior positions at large and small public and private life science companies. Jacqueline’s legal experience is focused on securities, pharmaceutical regulatory and intellectual property law. As a Vice President, Legal in both public and private companies Ms. Le Saux has led multiple financings, mergers and acquisitions and product licensing transactions, mitigating risk and executing strategies in the Canadian healthcare industry. Her broad industry experience spans big pharma to early and late-stage research and development, as well as consumer products and pharmaceutical manufacturing. Prior to entering the health care industry, she was a partner at a top tier Canadian law firm, specializing in securities and corporate law.

Bruce Rowlands

Bruce Rowlands has held the position of Chairman since May 2018 and a director of XORTX Pharma Corp., the Company’s predecessor since 2014. Bruce is the former Chairman and CEO of Eurocontrol Technics Group Inc., a TSX Venture Exchange listed company. Prior to forming Eurocontrol, Bruce worked in the biotechnology and investment banking industries as Senior Vice President with Lorus Therapeutics, Inc. a leading Canadian biotechnology company and Vice President and Director of Dominick and Dominick Securities Canada, a Canadian investment banking firm.

Paul Van Damme, B COMM, CPA, MBA

Paul Van Damme has held senior positions with a number of Canadian and US public companies. His experience focused on the biotech industry in Toronto when he joined GlycoDesign, a private biotech company. While at Allelix Pharmaceuticals Inc., he participated in the sale of that company to NPS Pharmaceuticals, Inc. Paul is Managing Director, WCM Capital, a Director of OncoQuest Inc. and Chief Financial Officer for Structural Genomics Consortium, a UK-based charity. He holds a B.Comm. from the University of Toronto and a MBA from the Rotman School of Management. A Chartered Professional Accountant who worked for PricewaterhouseCoopers in its Toronto and London, UK offices, he has also been appointed Chair of the XORTX Audit Committee.